Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model.
Animals
Anti-Bacterial Agents
/ pharmacology
Biofilms
/ drug effects
Calgranulin A
/ physiology
Chronic Disease
Ciprofloxacin
/ pharmacology
Colony Count, Microbial
Cytokines
/ metabolism
Disease Models, Animal
Drug Synergism
Female
Host-Pathogen Interactions
Intercellular Signaling Peptides and Proteins
/ metabolism
Mice
Mice, Inbred BALB C
Pseudomonas Infections
/ immunology
Pseudomonas aeruginosa
/ drug effects
Wound Infection
/ immunology
Pseudomonas
biofilm
flouroquinolone
Journal
Pathogens and disease
ISSN: 2049-632X
Titre abrégé: Pathog Dis
Pays: United States
ID NLM: 101595366
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
28
01
2019
accepted:
29
04
2019
pubmed:
23
5
2019
medline:
5
6
2021
entrez:
23
5
2019
Statut:
ppublish
Résumé
The majority of chronic wounds are associated with bacterial biofilms recalcitrant to antibiotics and host responses. Immunomodulatory S100A8/A9 is suppressed in Pseudomonas aeruginosa biofilm infected wounds. We aimed at investigating a possible additive effect between S100A8/A9 and ciprofloxacin against biofilms. Thirty-two mice were injected with alginate-embedded P. aeruginosa following a third-degree burn. The mice were randomized into four groups receiving combination ciprofloxacin and S100A8/A9 or monotherapy ciprofloxacin, S100A8/A9 or a placebo and evaluated by host responses and quantitative bacteriology in wounds. In addition, in vitro checkerboard analysis was performed, with P. aeruginosa and ascending S100A8/A9 and ciprofloxacin concentrations. S100A8/A9 augmented the effect of ciprofloxacin in vivo by lowering the bacterial quantity compared to the placebo arm and the two monointervention groups (P < 0.0001). S100A8 and 100A9 were increased in the double-treated group as compared to the monointervention groups (P = 0.032, P = 0.0023). Tissue inhibitor of metalloproteinases-1 and keratinocyte\chemokine chemoattractant-1 were increased in the double-intervention group compared to the S100A8/A9 group (P = 0.050, P = 0.050). No in vitro synergism was detected. The observed ciprofloxacin-augmenting effect of S100A8/A9 in vivo was not confirmed by checkerboard analysis, indicating dependence on host cells for the S100A8/A9 effect. S100A8/A9 and ciprofloxacin is a promising therapy for optimizing chronic wound treatment.
Identifiants
pubmed: 31116394
pii: 5497298
doi: 10.1093/femspd/ftz027
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Calgranulin A
0
Cytokines
0
Intercellular Signaling Peptides and Proteins
0
S100a8 protein, mouse
0
Ciprofloxacin
5E8K9I0O4U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© FEMS 2020.